Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
Ultragenyx Pharmaceutical Reports Positive Phase III Data For Their Kyowa Hakko Kirin-Partnered Drug
Article By:
Lorimer Wilson
Thursday, April 20, 2017 2:54 AM EST
Ultragenyx Pharmaceutical Inc. has reported clearly positive Phase III data for their Kyowa Hakko Kirin-partnered drug for X-linked hypophosphatemia, and now they plan to hustle that data package to regulators at the FDA and EMA.
In this article: RARE
Ultragenyx Pharmaceutical Inc. Drug "UX007" Fails Phase II Trial - Stock Tumbles
Article By:
Lorimer Wilson
Thursday, March 23, 2017 1:23 PM EST
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases reported that its drug UX007 failed a Phase II trial causing its stock to plummet.
In this article: RARE
Ultragenyx Pharmaceutical Inc. Shares Fall As Seizure Drug Fails Study
Article By:
TickerTV
Thursday, March 23, 2017 12:31 PM EST
RARE opened trading yesterday at $77.73 which was up from the previous day’s trading close of $77.72. Shares closed trading yesterday at $78.36 and spiked down after market to $73.20, equivalent to a 7% decrease from the closing price.
In this article: RARE
Jefferies Sees 'Attractive Buying Opportunities' In Biotech
Article By:
The Fly
Tuesday, October 18, 2016 10:16 AM EST
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment.